Advances in glioblastoma multiforme treatment: New models for nanoparticle therapy

Frontiers in Physiology

Volumn 9, Issue MAR, 2018, Pages

  Ozdemir Kaynak, Elif ^a   Qutub, Amina A ^b   Yesil Celiktas, Ozlem ^a,c,d  

^a EGE UNIVERSITY   (Turkey)

^b Rice University   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Blood brain barrier modeling; Cytoscape; Delphinidin; Glioblastoma; Nanoparticle

Indexed keywords

BEVACIZUMAB; DELPHINIDIN; NANOPARTICLE; TEMOZOLOMIDE;

BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NANOMEDICINE; PERSONALIZED MEDICINE; REVIEW; SIGNAL TRANSDUCTION;

EID: 85044104001     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2018.00170     Document Type: Review

References (91)

1. Alfonso, J. C., Köhn-Luque, A., Stylianopoulos, T., Feuerhake, F., Deutsch, A., and Hatzikirou, H. (2016). Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights. Sci. Rep. 6:37283. doi: 10.1038/srep37283
2. Alifieris, C., and Trafalis, D. T. (2015). Glioblastoma multiforme: pathogenesis and treatment. Pharmacol. Ther. 152, 63-82. doi: 10.1016/j.pharmthera.2015.05.005
3. Amin, F. U., Shah, S. A., Badshah, H., Khan, M., and Kim, M. O. (2017). Anthocyanins encapsulated by PLGA PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Aß1-42-induced oxidative stress. J. Nanobiotechnol. 15, 12. doi: 10.1186/s12951-016-0227-4
4. Andres-Lacueva, C., Shukitt-Hale, B., Galli, R. L., Jauregui, O., Lamuale-Raventos, R. M., and Joseph, J. A. (2005). Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. Nutr. Neurosci. 8, 111-120. doi: 10.1080/10284150500078117
5. Aryal, M., Arvanitis, C. D., Alexander, P. M., and McDannold, N. (2014). Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv. Drug Deliv. Rev. 72, 94-109. doi: 10.1016/j.addr.2014.01.008
6. Bandara, S., Diehl, M., and Fricker, G. (2007). Mathematical model for the transport of Paclitaxel (Taxol) across the blood-brain barrier. Chem. Eng. Res. Des. 85, 1065-1071. doi: 10.1205/cherd06238
7. Béduneau, A., Saulnier, P., and Benoit, J. P. (2007). Active targeting of brain tumors using nanocarriers. Biomaterials 28, 4947-4967. doi: 10.1016/j.biomaterials.2007.06.011
8. Bicker, J., Alves, G., Fortuna, A., and Falcão, A. (2014). Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur. J. Pharm. Biopharm. 87, 409-432. doi: 10.1016/j.ejpb.2014.03.012
9. Böttger, K., Hatzikirou, H., Chauviere, A., and Deutsch, A. (2012). Investigation of the migration/proliferation dichotomy and its impact on avascular glioma invasion. Math. Model. Nat. Phenom. 7, 105-135. doi: 10.1051/mmnp/20127106
10. Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P. Y., Dirix, L. Y., Macdonald, D., et al. (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259-266. doi: 10.1023/A:1008382516636
11. Branco, J. R., Ferreira, J. A., and de Oliveira, P. (2014). Mathematical modeling of efficient protocols to control glioma growth. Math. Biosci. 255, 83-90. doi: 10.1016/j.mbs.2014.07.002
12. Chakrabarti, M., and Ray, S. K. (2015). Direct transfection of miR-137 mimics is more effective than DNA demethylation of miR-137 promoter to augment anti-tumor mechanisms of delphinidin in human glioblastoma U87MG and LN18 cells. Gene 573, 141-152. doi: 10.1016/j.gene.2015.07.034
13. Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., and Lesniak, M. S. (2014). Multifunctional nanoparticles for brain tumor imaging and therapy. Adv. Drug Deliv. Rev. 66, 42-57. doi: 10.1016/j.addr.2013.09.006
14. Chithrani, B. D., Ghazani, A. A., and Chan, W. C. (2006). Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662-668. doi: 10.1021/nl052396o
15. Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., et al. (2010). A multigene predictor of outcome in glioblastoma. Neuro. Oncol. 12, 49-57. doi: 10.1093/neuonc/nop007
16. Colombo, M. C., Giverso, C., Faggiano, E., Boffano, C., Acerbi, F., and Ciarletta, P. (2015). Towards the personalized treatment of glioblastoma: integrating patient-specific clinical data in a continuous mechanical model. PLoS ONE 10:e0132887. doi: 10.1371/journal.pone.0132887
17. Decuzzi, P., and Ferrari, M. (2008). The receptor-mediated endocytosis of nonspherical particles. Biophys. J. 94, 3790-3797. doi: 10.1529/biophysj.107.120238
18. Demeule, M., Régina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., et al. (2002). Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 38, 339-348. doi: 10.1016/S1537-1891(02)00201-X
19. Dilnawaz, F., and Sahoo, S. K. (2013). Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur. J. Pharm. Biopharm. 85, 452-462. doi: 10.1016/j.ejpb.2013.07.013
20. Dunn, S., Constantinides, A., and Moghe, P. V. (2006). Numerical Methods in Biomedical Engineering. New York, NY: Academic Press; Elsevier.
21. Eikenberry, S. E., Sankar, T., Preul, M. C., Kostelich, E. J., Thalhauser, C. J., and Kuang, Y. (2009). Virtual glioblastoma: growth, migration and treatment in a three-dimensional mathematical model. Cell Prolif. 42, 511-528. doi: 10.1111/j.1365-2184.2009.00613.x
22. Escribá, P. V., Busquets, X., Inokuchi, J. I., Balogh, G., Török, Z., Horváth, I., et al. (2015). Membrane lipid therapy: Modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment. Prog. Lipid Res. 59, 38-53. doi: 10.1016/j.plipres.2015.04.003
23. Evans, C. J., Phillips, R. M., Jones, P. F., Loadman, P. M., Sleeman, B. D., Twelves, C. J., et al. (2009). A mathematical model of doxorubicin penetration through multicellular layers. J. Theor. Biol. 257, 598. doi: 10.1016/j.jtbi.2008.11.031
24. Fakhari, A., Baoum, A., Siahaan, T. J., Le, K. B., and Berkland, C. (2011). Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J. Pharm. Sci. 100, 1045-1056. doi: 10.1002/jps.22342
25. Fakhoury, M. (2015). Drug delivery approaches for the treatment of glioblastoma multiforme. Artif. Cells Nanomed. Biotechnol. 1401, 1-9. doi: 10.3109/21691401.2015.1052467
26. Fernandez-Piñeiro, I., Badiola, I., and Sanchez, A. (2017). Nanocarriers for microRNA delivery in cancer medicine. Biotechnol. Adv. 35, 350-360. doi: 10.1016/j.biotechadv.2017.03.002
27. Fine, H. A., Dear, K. B., Loeffler, J. S., Black, P. M., and Canellos, G. P. (1993). Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597. doi:10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S
28. Francescone, R., Scully, S., Bentley, B., Yan, W., Taylor, S. L., Oh, D., et al. (2012). Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J. Biol. Chem. 287, 24821-24831. doi: 10.1074/jbc.M111.334540
29. Frieboes, H. B., Lowengrub, J. S., Wise, S., Zheng, X., Macklin, P., Bearer, E., et al. (2007). Computer simulation of glioma growth and morphology. Neuroimage 37, 59-70. doi: 10.1016/j.neuroimage.2007.03.008
30. Frieboes, H. B., Wu, M., Lowengrub, J., Decuzzi, P., and Cristini, V. (2013). A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS ONE 8:e56876. doi: 10.1371/journal.pone.0056876
31. Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., et al. (2009). Bevacizumab alone and in combination with Irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740. doi: 10.1200/JCO.2008.19.8721
32. Frosina, G. (2015). Limited advances in therapy of glioblastoma trigger re-consideration of research policy. Crit. Rev. Oncol. Hematol. 96, 257-261. doi: 10.1016/j.critrevonc.2015.05.013
33. Galvano, F., La Fauci, L., Lazzarino, G., Fogliano, V., Ritieni, A., Ciappellano, S., et al. (2004). Cyanidins: metabolism and biological properties. J. Nutr. Biochem. 15, 2-11. doi: 10.1016/j.jnutbio.2003.07.004
34. Gevertz, J. L. (2011). Computational modeling of tumor response to vascular-targeting therapies- Part I: validation. Comput. Math. Methods Med. 2011:830515. doi: 10.1155/2011/830515
35. Gevertz, J. L., Gillies, G. T., and Torquato, S. (2008). Simulating tumor growth in confined heterogeneous environments. Phys. Biol. 5:036010. doi: 10.1088/1478-3975/5/3/036010
36. Gosk, S., Vermehren, C., Storm, G., and Moos, T. (2004). Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow. Metab. 24, 1193-1204. doi: 10.1097/01.WCB.0000135592.28823.47
37. Groh, C. M., Hubbard, M. E., Jones, P. F., Loadman, P. M., Periasamy, N., Sleeman, B. D., et al. (2014). Mathematical and computational models of drug transport in tumours. J. R. Soc. Interface 11:20131173. doi: 10.1098/rsif.2013.1173
38. Grover, A., Hirani, A., and Sutariya, V. (2014). Blood-brain barrier permeation of glutathione-coated nanoparticle. SOJ Pharm. Pharm. Sci. 4, 2-5. doi: 10.15226/2374-6866/1/1/00103
39. Hanada, S., Fujioka, K., Inoue, Y., Kanaya, F., Manome, Y., and Yamamoto, K. (2014). Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification. Int. J. Mol. Sci. 15, 1812-1825. doi: 10.3390/ijms15021812
40. Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003. doi: 10.1056/NEJMoa043331
41. Huang, S., Shao, K., Kuang, Y., Liu, Y., Li, J., An, S., et al. (2013a). Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 34, 5294-5302. doi: 10.1016/j.biomaterials.2013.03.043
42. Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., et al. (2013b). Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 7, 2860-2871. doi: 10.1021/nn400548g
43. Huang, Y., Arifin, D. Y., and Wang, C. H. (2009). Three-dimensional simulation of paclitaxel delivery to a brain tumor. Brain 1, 2. Available online at: http://pdfs.semanticscholar.org/ceca/6a347a1342e8a94919c5682519b0bf4e366b.pdf
44. Jain, R. K., and Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664. doi: 10.1038/nrclinonc.2010.139
45. Jo, D. H., Kim, J. H., Lee, T. G., and Kim, J. H. (2015). Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases. Nanomedicine 11, 1603-1611. doi: 10.1016/j.nano.2015.04.015
46. Kawadkar, J. I., Chauhan, M. K., and Maharana, M. A. (2011). Nanobiotechnology: application of nanotechnology in diagnosis, drug discovery and drug development. Asian J. Pharm. Clin. Res. 4, 23-28. Available online at: http://www.ajpcr.com/Vol4Issue1/218.pdf
47. Kim, M., Gillies, R. J., and Rejniak, K. A. (2013). Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front. Oncol. 3:278. doi: 10.3389/fonc.2013.00278
48. Kim, M. J., Rehman, S. U., Amin, F. U., and Kim, M. O. (2017). Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Aß1-42-induced neuroinflammation and neurodegeneration via the NF-KB/ JNK/ GSK3ß signaling pathway. Nanomedicine 13, 2533-2544. doi: 10.1016/j.nano.2017.06.022
49. Kim, S. S., Harford, J. B., Pirollo, K. F., and Chang, E. H. (2015). Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine. Biochem. Biophys. Res. Commun. 468, 485-489. doi: 10.1016/j.bbrc.2015.06.137
50. Krakstad, C., and Chekenya, M. (2010). Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol. Cancer 9:135. doi: 10.1186/1476-4598-9-135
51. Langlet, F. (2014). Tanycytes: a gateway to the metabolic hypothalamus. J. Neuroendocrinol. 26, 753-760. doi: 10.1111/jne.12191
52. Langlet, F., Mullier, A., Bouret, S. G., Prevot, V., and Dehouck, B. (2013). Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J. Comp. Neurol. 521, 3389-3405. doi: 10.1002/cne.23355
53. Lauzon, M. A., Daviau, A., Marcos, B., and Faucheux, N. (2015). Nanoparticle-mediated growth factor delivery systems: a new way to treat Alzheimer's disease. J. Control. Release 206, 187-205. doi: 10.1016/j.jconrel.2015.03.024
54. Lin, K. W., Liao, A., and Qutub, A. A. (2015). Simulation predicts IGFBP2-HIF1a interaction drives glioblastoma growth. PLOS Comput. Biol. 11:e1004169. doi: 10.1371/journal.pcbi.1004169
55. Liu, Y., and Lu, W. (2012). Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin. Drug Deliv. 9, 671-686. doi: 10.1517/17425247.2012.682726
56. Martins, S., Mussatto, S. I., Martínez-Avila, G., Monta-ez-Saenz, J., Aguilar, C. N., and Teixeira, J. A. (2011). Bioactive phenolic compounds: production and extraction by solid-state fermentation. A review. Biotechnol. Adv. 29, 365-373. doi: 10.1016/j.biotechadv.2011.01.008
57. Martirosyan, N. L., Rutter, E. M., Ramey, W. L., Kostelich, E. J., Kuang, Y., and Preul, M. C. (2015). Mathematically modeling the biological properties of gliomas: a review. Math. Biosci. Eng. 12, 879-905. doi: 10.3934/mbe.2015.12.879
58. Matsson, P., and Bergström, C. A. (2015). Computational modeling to predict the functions and impact of drug transporters. Silico Pharmacol. 3, 8. doi: 10.1186/s40203-015-0012-3
59. McLendon, R., Friedman, A., Bigner, D., Van Meir, E. G., Brat, D. J., Mastrogianakis, G. M., et al. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
60. Nduom, E. K., Bouras, A., Kaluzova, M., and Hadjipanayis, C. G. (2012). Nanotechnology applications for glioblastoma. Neurosurg. Clin. N. Am. 23, 439-449. doi: 10.1016/j.nec.2012.04.006
61. Neal, M. L., Trister, A. D., Ahn, S., Baldock, A., Bridge, C. A., Guyman, L., et al. (2013). Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res. 73, 2976-2986. doi: 10.1158/0008-5472.CAN-12-3588
62. Qin, Y., Fu, M., Takahashi, M., Iwanami, A., Kuga, D., Rao, R. G., et al. (2014). Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. J. Biol. Chem. 289, 13974-13985. doi: 10.1074/jbc.M113.543728
63. Quigley, M. R., and Maroon, J. C. (1991). The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29, 385-388. Discussion: 388-389. doi: 10.1227/00006123-199109000-00008
64. Reppas, A. I., Alfonso, J. C., and Hatzikirou, H. (2016). In silico tumor control induced via alternating immunostimulating and immunosuppressive phases. Virulence 7, 174-186. doi: 10.1080/21505594.2015.1076614
65. Rockne, R. C., Trister, A. D., Jacobs, J., Hawkins-Daarud, A. J., Neal, M. L., Hendrickson, K., et al. (2004). A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET. J. R. Soc. Interface 12:20141174. doi: 10.1098/rsif.2014.1174
66. Rutter, E. M., Stepien, T. L., Anderies, B. J., Plasencia, J. D., Woolf, E. C., Scheck, A. C., et al. (2017). Mathematical analysis of glioma growth in a murine model. Sci. Rep. 7:2508. doi: 10.1038/s41598-017-02462-0
67. Salata, O. (2004). Applications of nanoparticles in biology and medicine. J. Nanobiotechnol. 2:3. doi: 10.1186/1477-3155-2-3
68. Salazar, O. M., Rubin, P., Feldstein, M. L., and Pizzutiello, R. (1979). High dose radiation therapy in the treatment of malignant gliomas: final report. Int. J. Radiat. Oncol. Biol. Phys. 5, 1733-1740. doi: 10.1016/0360-3016(79)90554-6
69. Salcman, M. (1988). Surgical resection of malignant brain tumors: who benefits? Oncology 2, 47-56, 59-60, 63.
70. Saltzman, W. M., and Radomsky, M. L. (1991). Drugs released from polymers: diffusion and elimination in brain tissue. Chem. Eng. Sci. 46, 2429-2444. doi: 10.1016/0009-2509(91)80036-X
71. Schlüter, D. K., Ramis-Conde, I., and Chaplain, M. A. J. (2012). Computational modeling of single-cell migration: the leading role of extracellular matrix fibers. Biophys. J. 6, 1141-1151. doi: 10.1016/j.bpj.2012.07.048
72. Séhédic, D., Cikankowitz, A., Hindré, F., Davodeau, F., and Garcion, E. (2015). Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol. Sci. 36, 236-252. doi: 10.1016/j.tips.2015.02.002
73. Swanson, K. R., Rockne, R. C., Claridge, J., Chaplain, M. A., Alvord, E. C., and Anderson, A. R. (2011). Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res. 71, 7366-7375. doi: 10.1158/0008-5472.CAN-11-1399
74. Takae, S., Akiyama, Y., Otsuka, H., Nakamura, T., Nagasaki, Y., and Kataoka, K. (2005). Ligand density effect on biorecognition by PEGylated gold nanoparticles: regulated interaction of RCA120 lectin with lactose installed to the distal end of tethered PEG strands on gold surface. Biomacromolecules 6, 818-824. doi: 10.1021/bm049427e
75. TCGA (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068. doi: 10.1038/nature07385
76. Tektonidis, M., Hatzikirou, H., Chauvière, A., Simon, M., Schaller, K., and Deutsch, A. (2011). Identification of intrinsic in vitro cellular mechanisms for glioma invasion. J. Theor. Biol. 287, 131-147. doi: 10.1016/j.jtbi.2011.07.012
77. The New WHO Classification of Tumors Affecting the Central Nervous System [WWW Document] (1993). Available online at: http://neurosurgery.mgh.harvard.edu/newwhobt.htm (Accessed May 24, 2017).
78. Thuy, M. N., Kam, J. K., Lee, G. C., Tao, P. L., Ling, D. Q., Cheng, M., et al. (2015). A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J. Clin. Neurosci. 22, 785-799. doi: 10.1016/j.jocn.2014.10.029
79. Timbie, K. F., Mead, B. P., and Price, R. J. (2015). Drug and gene delivery across the blood-brain barrier with focused ultrasound. J. Control. Release 219, 61-75. doi: 10.1016/j.jconrel.2015.08.059
80. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131-135. doi: 10.1016/j.addr.2010.03.011
81. Van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., and de Vries, H. E. (2015). Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 19, 1-12. doi: 10.1016/j.drup.2015.02.002
82. Walker, M. D., Green, S. B., Byar, D. P., Alexander Jr, E., Batzdorf, U., Brooks, W. H., et al. (1980). Randomized comparisons of radiotherapy and nitrosoureas for the treatment of maligant glioma after surgery. N. Engl. J. Med. 303, 1323-1329. doi: 10.1056/NEJM198012043032303
83. Watanabe, Y., Dahlman, E. L., Leder, K. Z., and Hui, S. K. (2016). A mathematical model of tumor growth and its response to single irradiation. Theor. Biol. Med. Model. 13, 6. doi: 10.1186/s12976-016-0032-7
84. Weber, A. M., and Ryan, A. J. (2015). ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 149, 124-138. doi: 10.1016/j.pharmthera.2014.12.001
85. Wei, X., Chen, X., Ying, M., and Lu, W. (2014). Brain tumor-targeted drug delivery strategies. Acta Pharm. Sin. B 4, 193-201. doi: 10.1016/j.apsb.2014.03.001
86. Wen, P. Y., and Kesari, S. (2008). Malignant gliomas in adults. New Engl. J. Med. 359, 492-507. doi: 10.1056/NEJMra0708126
87. Whittle, J. R., Lickliter, J. D., Gan, H. K., Scott, A. M., Simes, J., Solomon, B. J., et al. (2015). First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J. Clin. Neurosci. 22, 1889-1894. doi: 10.1016/j.jocn.2015.06.005
88. Wilson, C. B. (1976). Chemotherapy of brain tumors. Adv. Neurol. 15, 361-367.
89. Yung, W. K., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Freidman, H. S., et al. (1999). Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal. Brain Tumor. Group. J. Clin. Oncol. 17, 2762-2771. doi: 10.1200/JCO.1999.17.9.2762
90. Zhang, L., Athale, C. A., and Deisboeck, T. S. (2007). Development of three-dimensional multiscale agent-based tumor model: simulating gene protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. J. Theor. Biol. 244, 96-107. doi: 10.1016/j.jtbi.2006.06.034
91. Zhou, J., Atsina, K. B., Himes, B. T., Strohbehn, G. W., and Saltzman, W. M. (2012). Novel delivery strategies for glioblastoma. Cancer J. 18, 1-22. doi: 10.1097/PPO.0b013e318244d8ae